Indeed, although anti-VEGF therapies (i.e., anti-VEGF or anti-VEGFR2 mAbs) or TKIs have shown promising results in preclinical studies, they failed to show a sizable efficacy in MM patients, suggesting that other factors (i.e., extracellular vesicles, miRNAs, lncRNAs, cytokines mixture/cocktail) may be involved in the angiogenic process and may allow therapy escape and drug resistance [34,35,36,37,44,45]. Here, VEGFA is linked to Miyoshi myopathy.